Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|May 26, 2016
Understanding Molecular Subtypes of Sarcoma
Author(s)Brian A. Van Tine, MD, PhD
Brian A. Van Tine, MD, PhD, assistant professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses the importance of understanding molecular subtypes of sarcoma.
Advertisement
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
5